MicroRNAs in cardiovascular disease: From pathogenesis to prevention and treatment

Journal of Clinical Investigation

Volumn 123, Issue 1, 2013, Pages 11-18

  Quiat, Daniel ^a   Olson, Eric N ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAGOMIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; MICRORNA 122; MICRORNA 143; MICRORNA 145; MICRORNA 29; MICRORNA 375; STEROL REGULATORY ELEMENT BINDING PROTEIN;

ANTIDIABETIC ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; GENE DELETION; GENE EXPRESSION REGULATION; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; MUSCLE ISCHEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; TISSUE REGENERATION;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; HUMANS; MICRORNAS; OBESITY; RISK FACTORS;

EID: 84873817376     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI62876     Document Type: Review

References (97)

1. Cohen ML. Changing patterns of infectious disease. Nature. 2000;406(6797): 762-767.
2. National Heart, Lung, and Blood Institute. Chapter 4: Disease statistics. NHLBI Fact Book, Fiscal Year 2011. NIH Web site. http://www.nhlbi.nih.gov/ about/factbook/chapter4.htm. Accessed May 18, 2012.
3. WHO. Causes of Death 2008 Summary Tables. Geneva, Switzerland: World Health Organization; 2008.
4. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3): 155-159.
5. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature. 2011; 469(7330): 336-342.
6. Chang TC, Mendell JT. microRNAs in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet. 2007;8: 215-239.
7. Mendell JT, Olson EN. 2012. MicroRNAs in stress signaling and human disease. Cell. 2012; 148(6): 1172-1187.
8. Krutzfeldt J, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature. 2005;438(7068): 685-689.
9. Orom UA, Kauppinen S, Lund AH. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene. 2006;372: 137-141.
10. Obad S, et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet. 2011; 43(4): 371-378.
11. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2): 281-297.
12. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466(7308): 835-840.
13. Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature. 2008;455(7209): 64-71.
14. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation. 2000; 101(3): 329-335.
15. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996; 275(20): 1571-1576.
16. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001; 161(7): 996-1002.
17. Vasan RS, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18): 1291-1297.
18. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev. 1995; 75(3): 487-517.
19. Albinsson S, Suarez Y, Skoura A, Offermanns S, Miano JM, Sessa WC. MicroRNAs are necessary for vascular smooth muscle growth, differentiation, and function. Arterioscler Thromb Vasc Biol. 2010; 30(6): 1118-1126.
20. Albinsson S, et al. Smooth muscle miRNAs are critical for post-natal regulation of blood pressure and vascular function. PLoS One. 2011;6(4):e18869.
21. Xin M, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 2009; 23(18): 2166-2178.
22. Cordes KR, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009; 460(7256): 705-710.
23. Boettger T, et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest. 2009;119(9): 2634-2647.
24. Nossent AY, Hansen JL, Doggen C, Quax PH, Sheikh SP, Rosendaal FR. SNPs in microRNA binding sites in UTRs of RAAS genes influence arterial blood pressure and risk of myocardial infarction. Am J Hypertens. 2011;24(9): 999-1006.
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19): 2486-2497.
26. Kannel WB. Risk stratification of dyslipidemia: insights from the Framingham Study. Curr Med Chem Cardiovasc Hematol Agents. 2005;3(3): 187-193.
27. Fernandez ML, Webb D. The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk. J Am Coll Nutr. 2008;27(1): 1-5.
28. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in the development of coronary heart disease - six year follow-up experience. The Framingham Study. Ann Intern Med. 1961; 55: 33-50.
29. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986; 256(20): 2835-2838.
30. Sekine S, et al. Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis. Gastroenterology. 2009; 136(7): 2304-2315.
31. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89(3): 331-340.
32. Najafi-Shoushtari SH, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science. 2010;328(5985): 1566-1569.
33. Rayner KJ, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010; 328(5985): 1570-1573.
34. Dávalos A, et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A. 2011;108(22): 9232-9237.
35. Rayner KJ, et al. Inhibition of miR-33a/b in non- human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011;478(7369): 404-407.
36. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue- specific microRNAs from mouse. Curr Biol. 2002; 12(9): 735-739.
37. Chang J, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 2004;1(2): 106-113.
38. Xu H, et al. Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology. 2010; 52(4): 1431-1442.
39. Esau C, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3(2): 87-98.
40. Elmén J, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008; 452(7189): 896-899.
41. Lanford RE, et al. Therapeutic silencing of microRNA- 122 in primates with chronic hepatitis C virus infection. Science. 2010;327(5962): 198-201.
42. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979; 241(19): 2035-2038.
43. Lynn FC, Skewes-Cox P, Kosaka Y, McManus MT, Harfe BD, German MS. MicroRNA expression is required for pancreatic islet cell genesis in the mouse. Diabetes. 2007;56(12): 2938-2945.
44. Mudhasani R, Puri V, Hoover K, Czech MP, Imbalzano AN, Jones SN. Dicer is required for the formation of white but not brown adipose tissue. J Cell Physiol. 2011;226(5): 1399-1406.
45. Poy MN, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 2004; 432(7014): 226-230.
46. Zhao H, et al. Up-regulated pancreatic tissue microRNA-375 associates with human type 2 diabetes through beta-cell deficit and islet amyloid deposition. Pancreas. 2010;39(6): 843-846.
47. Poy MN, et al. miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci U S A. 2009;106(14): 5813-5818.
48. Herrera BM, et al. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia. 2010; 53(6): 1099-1109.
49. Trajkovski M, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011;474(7353): 649-653.
50. Jordan SD, et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol. 2011;13(4): 434-446.
51. Reinhart BJ, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403(6772): 901-906.
52. Zhu H, et al. Lin28a transgenic mice manifest size and puberty phenotypes identified in human genetic association studies. Nat Genet. 2010; 42(7): 626-630.
53. Zhu H, et al. The Lin28/let-7 axis regulates glucose metabolism. Cell. 2011;147(1): 81-94.
54. Frost RJ, Olson EN. Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. Proc Natl Acad Sci U S A. 2011; 108(52): 21075-21080.
55. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004;25(4): 543-567.
56. van Rooij E, et al. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell. 2009;17(5): 662-673.
57. Callis TE, et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest. 2009;119(9): 2772-2786.
58. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science. 2007;316(5824): 575-579.
59. Grueter CE, et al. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell. 2012;149(3): 671-683.
60. Chobanian AV, Alexander RW. Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications. Arch Intern Med. 1996;156(17): 1952-1956.
61. Rayner KJ, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest. 2011;121(7): 2921-2931.
62. Cheng Y, et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res. 2009;105(2): 158-166.
63. Ji R, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res. 2007;100(11): 1579-1588.
64. Hergenreider E, et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol. 2012; 14(3): 249-256.
65. Wang S, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15(2): 261-271.
66. Kuhnert F, et al. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development. 2008;135(24): 3989-3993.
67. Zernecke A, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009;2(100):ra81.
68. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74(5): 1124-1136.
69. Roy S, et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res. 2009; 82(1): 21-29.
70. Bostjancic E, Zidar N, Glavac D. MicroRNA microarray expression profiling in human myocardial infarction. Dis Markers. 2009;27(6): 255-268.
71. Aurora AB, et al. MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca2+ overload and cell death. J Clin Invest. 2012; 122(4): 1222-1232.
72. Wang JX, et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin- related protein-1. Nat Med. 2011;17(1): 71-78.
73. Olson EN, Williams RS. Calcineurin signaling and muscle remodeling. Cell. 2000;101(7): 689-692.
74. Shieh JT, Huang Y, Gilmore J, Srivastava D. Elevated miR-499 levels blunt the cardiac stress response. PLoS One. 2011;6(5):e19481.
75. Dorn GW 2nd, Matkovich SJ, Eschenbacher WH, Zhang Y. A human miR-499 mutation alters cardiac mRNA targeting and function. Circ Res. 2012; 110(7): 958-967.
76. da Costa Martins PA, et al. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation. 2008; 118(15): 1567-1576.
77. Rao PK, et al. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ Res. 2009;105(6): 585-594.
78. van Rooij E, et al. A signature pattern of stress- responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A. 2006;103(48): 18255-18260.
79. Thum T, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation. 2007;116(3): 258-267.
80. Thum T, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456(7224): 980-984.
81. Patrick DM, et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest. 2010;120(11): 3912-3916.
82. da Costa Martins PA, et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol. 2010;12(12): 1220-1227.
83. Montgomery RL, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation. 2011; 124(14): 1537-1547.
84. van Rooij E, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A. 2008; 105(35): 13027-13032.
85. Maegdefessel L, et al. Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J Clin Invest. 2012;122(2): 497-506.
86. Boon RA, et al. MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ Res. 2011; 109(10): 1115-1119.
87. Kikuchi K, et al. Primary contribution to zebrafish heart regeneration by gata4(+) cardiomyocytes. Nature. 2010;464(7288): 601-605.
88. Porrello ER, et al. Transient regenerative potential of the neonatal mouse heart. Science. 2011; 331(6020): 1078-1080.
89. Jopling C, Sleep E, Raya M, Martí M, Raya A, Izpisúa Belmonte JC. Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. Nature. 2010;464(7288): 606-609.
90. Porrello ER, et al. MiR-15 family regulates postnatal mitotic arrest of cardiomyocytes. Circ Res. 2011; 109(6): 670-679.
91. Hullinger TG, et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res. 2012; 110(1): 71-81.
92. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006;25(46): 6188-6196.
93. Viswanathan SR, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009;41(7): 843-848.
94. Esquela-Kerscher A, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle. 2008;7(6): 759-764.
95. Wang WC, Juan AH, Panebra A, Liggett SB. MicroRNA let-7 establishes expression of beta2- adrenergic receptors and dynamically down-regulates agonist-promoted down-regulation. Proc Natl Acad Sci U S A. 2011;108(15): 6246-6251.
96. Fichtlscherer S, Zeiher AM, Dimmeler S. Circulating microRNAs: biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol. 2011; 31(11): 2383-2390.
97. Santaris Pharma A/S. Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects. NIH Web site. http://clinicaltrials.gov/ct2/show/record/NCT01200420. Updated January 26, 2012. Accessed May 18, 2012.